MX2007001114A - Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano. - Google Patents

Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.

Info

Publication number
MX2007001114A
MX2007001114A MX2007001114A MX2007001114A MX2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A
Authority
MX
Mexico
Prior art keywords
ckd
lanthanum hydroxycarbonate
hyperphosphataemia
suffering
susceptible
Prior art date
Application number
MX2007001114A
Other languages
English (en)
Inventor
Josephine Christine Ferdinando
David Gilmour
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of MX2007001114A publication Critical patent/MX2007001114A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripcion se refiere al tratamiento de sujetos en riesgo de enfermedad renal cronica (CKD), que tiene CKD de etapa uno a cinco, que tiene hiperfosfatemia, que es susceptible a calcificacion de tejido blando asociada con CKD o que la padece, o que es susceptible a hiperparatiroidismo o que lo padece, al administrar oralmente una composicion farmaceutica que contiene una cantidad terapeuticamente efectiva de hidroxicarbonato de lantano.
MX2007001114A 2004-07-27 2005-07-27 Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano. MX2007001114A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59110504P 2004-07-27 2004-07-27
PCT/US2005/026668 WO2006015055A1 (en) 2004-07-27 2005-07-27 Method of treating hyperphosphataemia using lanthanum hydroxycarbonate

Publications (1)

Publication Number Publication Date
MX2007001114A true MX2007001114A (es) 2007-07-11

Family

ID=35787449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007001114A MX2007001114A (es) 2004-07-27 2005-07-27 Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.

Country Status (14)

Country Link
US (1) US20060153932A1 (es)
EP (1) EP1708723A4 (es)
JP (1) JP4869229B2 (es)
KR (2) KR101072196B1 (es)
CN (1) CN101018555A (es)
AU (1) AU2005269362B2 (es)
BR (1) BRPI0513603A (es)
CA (1) CA2574450C (es)
EA (1) EA010980B1 (es)
MX (1) MX2007001114A (es)
NO (1) NO20070906L (es)
NZ (1) NZ552861A (es)
WO (1) WO2006015055A1 (es)
ZA (1) ZA200701707B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
HUE024906T2 (en) * 2003-08-26 2016-02-29 Shire Biopharmaceuticals Holdings Ireland Ltd Pharmaceutical composition containing lanthanum compounds
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
JP2009504779A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における慢性腎不全及びその他の病気の治療：組成物及び方法
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
CN101374416A (zh) * 2006-01-30 2009-02-25 环亚有限公司 逆转、防止、延迟或稳定软组织钙化的方法
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP1852695B1 (en) * 2006-05-05 2011-10-26 Shire International Licensing B.V. Assay for lanthanum hydroxy carbonate
US8961917B2 (en) * 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
GB201501000D0 (en) * 2015-01-21 2015-03-04 Univ Edinburgh Lanthanum thiosulfate and methods of preparation of the same
EP3368078A1 (en) * 2015-10-27 2018-09-05 Medice Arzneimittel Pütter GmbH & Co. KG Nicotinamide for lowering phosphate levels in hyperphosphatemia
JP6668496B2 (ja) 2015-12-01 2020-03-18 ヨン キム，ベ 生理活性物質複合体、その製造方法及びそれを含有する化粧料組成物
KR101684289B1 (ko) 2016-05-17 2016-12-09 한국식품연구원 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
US10322409B1 (en) * 2018-03-05 2019-06-18 King Fahd University Of Petroleum And Minerals Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592082A (en) * 1984-08-10 1986-05-27 The United States Of America As Represented By The United States Department Of Energy Quantitative determination of mineral composition by powder X-ray diffraction
EP0620728B1 (en) * 1992-01-13 1997-01-08 Pfizer Inc. Preparation of tablets of increased strength
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
US5435986A (en) * 1994-08-30 1995-07-25 Industrial Technology Research Institute Method for preparing high purity aluminum hydroxide
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1207896A4 (en) * 1999-09-02 2004-09-08 Acologix Inc METHOD AND COMPOSITIONS FOR REDUCING THE SERUM PHOSPHATE MIRROR
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
KR100956013B1 (ko) * 2001-04-23 2010-05-06 샤이어 인터내쇼날 라이센싱 비.브이. 희토류 화합물을 포함하는 신장 결석 질환 치료용 약제학적 조성물
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
HUE024906T2 (en) * 2003-08-26 2016-02-29 Shire Biopharmaceuticals Holdings Ireland Ltd Pharmaceutical composition containing lanthanum compounds
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions

Also Published As

Publication number Publication date
CA2574450C (en) 2011-07-19
CN101018555A (zh) 2007-08-15
KR101072196B1 (ko) 2011-10-10
AU2005269362A1 (en) 2006-02-09
WO2006015055A1 (en) 2006-02-09
KR20090023743A (ko) 2009-03-05
US20060153932A1 (en) 2006-07-13
KR20070054191A (ko) 2007-05-28
NO20070906L (no) 2007-04-23
EA200700273A1 (ru) 2007-08-31
JP2008508297A (ja) 2008-03-21
NZ552861A (en) 2010-11-26
ZA200701707B (en) 2008-10-29
EP1708723A4 (en) 2006-12-20
EA010980B1 (ru) 2008-12-30
AU2005269362B2 (en) 2010-08-12
CA2574450A1 (en) 2006-02-09
JP4869229B2 (ja) 2012-02-08
EP1708723A1 (en) 2006-10-11
BRPI0513603A (pt) 2008-05-13

Similar Documents

Publication Publication Date Title
MX2007001114A (es) Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
WO2007124461A8 (en) Glp-1 compounds
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
WO2007087468A3 (en) Adiponectin for treatment of various disorders
NZ609280A (en) Method for treatment of constipation-predominant irritable bowel syndrome
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EP2628486A3 (en) Method for treating bone fracture with anti-sclerostin antibodies
MY147391A (en) Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
WO2009064460A3 (en) Gastrointestinal delivery systems
TW200744642A (en) Novel peptides for use in the treatment of obesity
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
EP3276004A3 (en) Methods for treating chronic kidney disease
TW200740452A (en) Therapeutic gastrodia extracts
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
TW200742580A (en) Methods for treating nephrolithiasis
WO2006138043A3 (en) Method and compositions for the treatment of diabetes and related complications
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
WO2008019388A3 (en) Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome